Revenue grew 9% to 34.1 MSEK in 2024, with strong demand in pharma and food segments, but continued investments led to a net loss. A 13 MSEK convertible loan strengthens the balance sheet for further expansion and innovation.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.